Loading...
XNYS
LCTX
Market cap175mUSD
Oct 08, Last price  
1.03USD
1D
8.70%
1Q
-19.53%
Jan 2017
-67.39%
Name

Lineage Cell Therapeutics Inc

Chart & performance

D1W1MN
XNYS:LCTX chart
P/E
—
P/S
12.03
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.93%
Rev. gr., 5y
79.88%
Revenues
15m
+53.24%
1,162,0151,046,1211,503,7921,925,1683,680,3004,354,7621,692,8692,861,0071,946,3722,534,0002,252,0001,792,0001,416,0001,478,000773,0003,896,00014,703,0008,945,0009,499,00014,556,000
Net income
-64m
L+241.41%
-1,864,621-1,438,226-3,780,895-5,143,909-11,184,618-16,515,500-21,425,703-43,882,835-36,411,660-46,991,00033,572,000-19,976,000-45,990,000-11,709,000-20,649,000-43,019,000-26,273,000-21,486,000-18,609,000-63,533,000
CFO
-19m
L-18.07%
-1,262,219-1,239,980-1,604,245-4,259,938-7,732,884-13,593,916-19,679,518-29,508,613-38,854,200-44,544,000-42,326,000-30,517,000-30,882,000-31,947,000-19,753,000-23,561,0001,059,000-28,566,000-23,092,000-18,919,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BlackRock Technology and Private Equity Term Trust is a mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. BlackRock Technology and Private Equity Term Trust is domiciled in the United States.

Key people

Brian M. Culley
President, Chief Executive Officer, Director · since 2018
Brandi Roberts
Chief Financial Officer, Senior Vice President - Finance · since 2019
Gary S. Hogge
Senior Vice President of Clinical & Medical Affairs · since 2019
Chase C. Leavitt
General Counsel and Corporate Secretary · since 2019
Alfred D. Kingsley
Chairman of the Board, Director · since 2009
Deborah J. Andrews
Independent Director · since 2014
Don M. Bailey
Independent Director · since 2019
Neal C. Bradsher
Independent Director · since 2009
Stephen C. Farrell
Independent Director · since 2013
Michael H. Mulroy
Independent Director · since 2014
Angus Charles Russell
Independent Director · since 2014
URL
https://lineagecell.com/
IPO date
Mar 05, 1992
Employees
70
Domiciled in
US
Incorporated in
US
Headquarters & legal address
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT